drugset / Trial / NCT06490939

Clinical Trial of Efepoetin Alfa in Healthy Subjects

NCT06490939

Phase 1 Completed 40 enrolled Genexine, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

An open-label, parallel-group, single-center, Phase I study to compare the pharmacokinetic/pharmacodynamic characteristics, safety, and tolerability of a single intravenous administration of Efepoetin Alfa in healthy subjects

Timeline

Start
2024-10-29
Primary completion
2025-03-25
Completion
2025-03-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Efepoetin Alfa Protein / enzyme biologic Intravenous

Indications

No indication recorded.